Skip to main content
Premium Trial:

Request an Annual Quote

ARUP Labs to Offer Decode's Prostate Cancer Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ARUP Laboratories will begin offering Decode Genetics' prostate cancer test in the fall under a deal announced today.

ARUP will offer Decode's ProstateCancer test to academic medical centers, public and private healthcare providers, and major hospitals in the US as part of its portfolio of tests. The test will be ordered through ARUP, which will handle patient samples and results. Decode will analyze the samples in its CAP and CLIA-certified laboratory.

The two companies did not reveal the terms of the agreement.

The ProstateCancer test measures 25 common SNPs associated with prostate cancer risk. In a statement, the companies said that the test can identify about 15 percent of men who are at double the average risk of prostate cancer and 5 percent of men who are at triple the average risk.

The test is meant as a complement to standard clinical risk screening methods, such as PSA.

ARUP is a reference laboratory owned by the University of Utah.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.